Yesterday, Circio Holding presented the circVec platform and its potential at two international industry conferences. We continue to like the focus on the circRNA programme, but the company is still in an early stage and the funding situation remains unclear to us.
We continue to believe Circio’s technology has significant potential and that the company will successfully secure a partnering deal. However, while we estimate it has secured a runway through H1 2025, the funding situation remains unclear to us, and we thus continue to have no recommendation or target price on Circio.
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease - Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced...
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024 LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently n...
We continue to like Circio’s focus on the circRNA programme and believe it will be able to secure a partnering deal in 2025. However, the funding situation is unclear. It recently announced an intention to raise cNOK50m–60m in Q2. As we have limited input on the terms of the upcoming capital raise and Atlas Capital Markets’ (the counterparty of the convertible bond facility announced in February 2023) degree of participation and conditions, we have withdrawn our target price and recommendation.
Targovax announced its intention to rebrand as Circio to reflect its strategic shift to focus on further development of its proprietary and innovative circular RNA platform. Subject to shareholder approval, Circio Holding ASA will assume the Targovax ASA listing on Oslo stock exchange under the ticker CRNA.
Yesterday, Targovax announced its strategic decision to prioritise its resources on its circRNA platform. We believe this is a right strategic move, since it should leave the company less dependent on the convertible loan financing and since we believe these efforts have the potential to create substantial shareholder value (we now estimate that a deal in circRNA could materialise 6–12 months following proof-of-concept data, expected in H1 2023). With financing secured at what we consider to be ...
We agree with the CEO that the company’s circular RNA programme represents a large opportunity and an attractive target for partnering. We estimate that a deal in circular RNA could materialise in 2023 and we still see considerable upside potential from the current share price. Following change of analyst, we reiterate our BUY and NOK4 target price.
The operating cost base was slightly higher than forecast, but we see no drama here given the work being conducted ahead of its clinical trials. The end-Q1 cash position was cNOK150m and, as the company’s most important trial will not start until late 2022/early 2023, it needs to conserve cash to finance it. The deal struck with Agenus lowers the cost of the phase II trial but with the added risk that ONCOS-102 is combined with two still unapproved drugs. We reiterate our BUY but have cut our ta...
We reinstate a recommendation and target price after the recent capital raise. Targovax reported a Q4 operating loss in line with our forecast. Its next important step will be to initiate the next clinical trial for ONCOS-102 in malignant melanoma, with the trial set to start in late Q4 this year or early next year. The company ended 2021 with cNOK181m in cash, so its financial situation is stronger now than before the capital raising. We reinstate our BUY with a NOK4.5 target price.
With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...
With the investigational new drug (IND) application approved by the FDA, Abliva is getting ready for the pivotal Phase II/III trial for its lead drug candidate KL1333, NAD+ modulator expected to increase cellular energy production in primary mitochondrial disorder (PMD) patients. Phase Ia/b data with first findings from treating patients were published in 2021. Abliva is now focused on finalising the regulatory approvals in other countries. Another major focus for the management is to establish ...
In connection with its Q3 report, Targovax announced a fully underwritten rights issue of shares amounting to cNOK175m, which should extend its runway to Q3 2023. The actual results were something of a non-event (as is common for biotech development companies). We have withdrawn our recommendation and target price due to DNB Markets’ role in the proposed upcoming rights issue.
While the Q2 operating loss was slightly smaller than we forecast, cash on the balance sheet at quarter-end was in line. However, the key takeaway was disclosure of the next step in the development for ONCOS-102 in melanoma (based on scientific advice received from the FDA); the phase II development for this indication should commence in H1 2022. We reiterate our BUY and NOK17 target price.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.